MedTrace Logo

Topical Preparation of Pomegranate and Ginkgo Biloba for Anti-aging Activities

NCT03772418 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-12-11

No results posted yet for this study

Summary

As the quality of life improves, people are seeking to look as young as they feel. Ginkgo biloba (GB) and Pomegranate (PG) extract can be used to create efficacious topical anti-aging products. GB \& PG are now widely used in research and clinical trials on age-associated diseases, for example, skin aging, brain dysfunction, cardiovascular system diseases, carcinogen metabolism. The investigator's aim is to formulate a topical cream in the form (O/W or W/O emulsion) formulation, containing GB as an anti-aging formulation for the public.

Conditions

  • Skin and Subcutaneous Tissue Disorders

Interventions

DRUG

Cream Base

The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.

DRUG

Pomegrante and Ginkgo biloba group

The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).

Sponsors & Collaborators

  • Ahmed A. H. Abdellatif

    lead OTHER

Principal Investigators

  • Ahmed Abdellatif, Ph.D. · Assistant Prof. at Pharmaceutics dept., Faculty of Pharmacy, Qassim University, KSA

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-18
Primary Completion
2020-01-01
Completion
2020-02-28

Countries

  • Egypt
  • Saudi Arabia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03772418 on ClinicalTrials.gov